Arcutis Biotherapeutics (ARQT) News Today

→ AI “wealth window” is closing soon! (From Paradigm Press) (Ad)

$10.09

-0.11 (-1.08%)

(As of 04/15/2024 ET)

Source

Source	Headline
	Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 8.8% americanbankingnews.com - April 14 at 3:46 AM
	Arcutis Biotherapeutics' (ARQT) Buy Rating Reaffirmed at Needham & Company LLC americanbankingnews.com - April 14 at 2:46 AM
	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Short Interest Update marketbeat.com - April 13 at 12:23 PM
	Arcutis Biotherapeutics Inc Ordinary Shares ARQT morningstar.com - April 12 at 3:06 PM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Stock Price Down 8.8% marketbeat.com - April 12 at 12:46 PM
	Analysts Are Bullish on These Healthcare Stocks: GoodRx Holdings (GDRX), Arcutis Biotherapeutics (ARQT) markets.businessinsider.com - April 12 at 10:06 AM
	Evaluating Arcutis Biotherapeutics: Insights From 5 Financial Analysts markets.businessinsider.com - April 12 at 10:06 AM
	Arcutis Biotherapeutics' (ARQT) "Buy" Rating Reiterated at Needham & Company LLC marketbeat.com - April 12 at 8:14 AM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Down to $12.49 americanbankingnews.com - April 12 at 6:32 AM
	Investors Buy Large Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT) americanbankingnews.com - April 11 at 2:34 AM
	Arcutis Biotherapeutics, Inc.: Arcutis Appoints David Topper as Chief Financial Officer finanznachrichten.de - April 10 at 9:22 PM
	Arcutis Biotherapeutics Appoints David Topper To Succeed John Smither As CFO markets.businessinsider.com - April 10 at 4:21 PM
	Traders Buy Large Volume of Call Options on Arcutis Biotherapeutics (NASDAQ:ARQT) marketbeat.com - April 10 at 1:38 PM
	Arcutis Biotherapeutics Names David Topper as Finance Chief marketwatch.com - April 10 at 8:51 AM
	Buy Rating on Arcutis Biotherapeutics Bolstered by Projected Q1 Sales Beat and 2024 Upside Potential markets.businessinsider.com - April 10 at 8:51 AM
	Arcutis Biotherapeutics appoints CFO msn.com - April 10 at 8:51 AM
	Arcutis Appoints David Topper as Chief Financial Officer globenewswire.com - April 10 at 8:00 AM
	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) globenewswire.com - April 5 at 4:00 PM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 8% marketbeat.com - April 4 at 2:03 PM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Down 6.2% marketbeat.com - April 1 at 3:48 PM
	Stock Traders Buy High Volume of Put Options on Arcutis Biotherapeutics (NASDAQ:ARQT) marketbeat.com - April 1 at 12:43 PM
	Sol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream finance.yahoo.com - April 1 at 7:32 AM
	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference finance.yahoo.com - March 28 at 8:12 AM
	Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference globenewswire.com - March 28 at 8:00 AM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Up 2.8% marketbeat.com - March 22 at 12:06 PM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 4.6% marketbeat.com - March 21 at 5:43 PM
	ARQT May 2024 10.000 call finance.yahoo.com - March 19 at 8:11 PM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Gap Down to $10.66 marketbeat.com - March 18 at 11:25 AM
	Short Interest in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Declines By 6.8% marketbeat.com - March 18 at 11:24 AM
	Insider Selling: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Insider Sells 3,760 Shares of Stock insidertrades.com - March 16 at 10:59 AM
	ATHA Apr 2024 2.500 put finance.yahoo.com - March 15 at 11:09 PM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Shares Up 7.2% marketbeat.com - March 13 at 2:58 PM
	ARQT Apr 2024 12.500 call finance.yahoo.com - March 11 at 11:51 PM
	ARQT Apr 2024 5.000 call finance.yahoo.com - March 11 at 1:50 PM
	Arcutis Biotherapeutics (NASDAQ:ARQT) Trading Down 7.7% marketbeat.com - March 11 at 12:44 PM
	ARQT Apr 2024 2.500 call finance.yahoo.com - March 11 at 8:50 AM
	Arcutis Promotes Todd Tucker to Chief Human Resources Officer globenewswire.com - March 11 at 8:00 AM
	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Brokerages marketbeat.com - March 11 at 4:19 AM
	Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting globenewswire.com - March 10 at 4:00 PM
	New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction globenewswire.com - March 9 at 4:00 PM
	Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) globenewswire.com - March 5 at 4:00 PM
	Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares globenewswire.com - March 4 at 4:00 PM
	Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting globenewswire.com - March 4 at 8:00 AM
	Fmr LLC Lowers Stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) marketbeat.com - March 2 at 5:13 AM
	Earnings Beat: Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts finance.yahoo.com - March 1 at 9:35 AM
	74,293 Shares in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Purchased by Dark Forest Capital Management LP marketbeat.com - March 1 at 5:23 AM
	Arcutis Biotherapeutics, Inc. (ARQT) Q4 2023 Earnings Call Transcript seekingalpha.com - March 1 at 12:29 AM
	Arcutis to Present at the TD Cowen 44th Annual Health Care Conference globenewswire.com - February 29 at 5:00 PM
	Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Q4 2023 Earnings Call Transcript finance.yahoo.com - February 29 at 2:28 PM
	Arcutis Biotherapeutics, Inc.: Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan finanznachrichten.de - February 29 at 9:28 AM

Get Arcutis Biotherapeutics News Delivered to You Automatically

A.I. “Perfect Storm” Could Send THESE Stocks Sky High (Ad)

A little-known investment analyst whose performance beat out 15,000+ other experts in 2020 has identified an opportunity in the A.I. space. He's calling it A.I.'s perfect storm.

>>Check out what this A.I. Perfect Storm is<<

ARQT Media Mentions By Week

ARQT Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ARQT
News Sentiment
▼
0.38

0.66
▲
Average
Medical
News Sentiment

ARQT News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ARQT Articles
This Week
▼
21

4
▲
ARQT Articles
Average Week

Get Arcutis Biotherapeutics News Delivered to You Automatically

Related Companies and Tools

Related Companies:

Headlines Tools:

This page (NASDAQ:ARQT) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Arcutis Biotherapeutics (ARQT) News Today

ARQT Media Mentions By Week

ARQT Media Sentiment

ARQT News Coverage

Related Companies and Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info